Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Dr Mike Bunce, Biofortuna’s CEO said “We are very excited about the launch of our first line of kits for Coeliac disease susceptibility and Abacavir hypersensitivity. Biofortuna’s blend of easy-to-use one-step PCR technology and multiplexing capability means we are confident of quickly taking market share. Having evaluated several automated systems, we have chosen to work with Lab901 because of the ease-of-use, cost-effectiveness and reproducibility of the ScreenTape platform".
Financial terms were not disclosed.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.